PlainPharmaWatch

CMS Open Payments · Tool

Cumberland Pharmaceuticals, Inc. vs ImmunoGen, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Cumberland Pharmaceuticals, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,083, versus 533 for the other company. Its single largest recorded recipient represents 0.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Cumberland Pharmaceuticals, Inc.
HHI 1,083 · top recipient 0.3%
Ranked #998 of 1,838 companies by HHI
ImmunoGen, Inc.
HHI 533 · top recipient 0.1%
Ranked #1,270 of 1,838 companies by HHI

Payment Overview

Total Payments
$918.2K
% of Industry
0.0%
Transactions
4,019
Avg per Transaction
$228.45
Recipients
3,940
Avg per Recipient
$233.03
Payment Types
5
Top Payment Type
Consulting Fee
Company B

ImmunoGen, Inc.

Total Payments
$919.6K
% of Industry
0.0%
Transactions
466
Avg per Transaction
$2.0K
Recipients
430
Avg per Recipient
$2.1K
Payment Types
5
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Cumberland Pharmaceuticals, Inc. vs ImmunoGen, Inc. - total reported payments in CMS Open Payments PY2024

ImmunoGen, Inc.$919.6KCumberland Pharmaceuticals,…$918.2K

Payment Types Breakdown

Cumberland Pharmaceuticals, Inc.

Consulting Fee $177.3K

19.3%

Compensation for Services Other Than Consulting $80.7K

8.8%

Food and Beverage $79.8K

8.7%

Travel and Lodging $3.4K

0.4%

Education $364.43

0.0%

ImmunoGen, Inc.

Compensation for Services Other Than Consulting $49.3K

5.4%

Consulting Fee $28.4K

3.1%

Food and Beverage $15.2K

1.6%

Travel and Lodging $2.7K

0.3%

Education $30.86

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Cumberland Pharmaceuticals, Inc.

  1. 1

    GORDON BERNARD

    $99,500.00 · 10 txns

  2. 2

    TODD RICE

    $36,152.98 · 11 txns

  3. 3

    VATSALA SASTRY

    $21,100.82 · 13 txns

  4. 4

    MICHAEL LEW

    $13,750.84 · 11 txns

  5. 5

    MOHAMED ERRITOUNI

    $13,125.00 · 4 txns

ImmunoGen, Inc.

  1. 1

    SUSANA CAMPOS

    $9,975.00 · 2 txns

  2. 2

    RUCHI GARG

    $9,727.50 · 13 txns

  3. 3

    HELEN THACKRAY

    $7,500.00 · 1 txns

  4. 4

    TIMMY NGUYEN

    $6,845.00 · 1 txns

  5. 5

    SHELLY SEWARD

    $6,698.27 · 4 txns

Summary Comparison

Metric Cumberland Pharmaceuticals, Inc. ImmunoGen, Inc.
Total Payments $918.2K $919.6K
% of Industry Total 0.0% 0.0%
Transaction Count 4,019 466
Avg per Transaction $228.45 $2.0K
Recipient Count 3,940 430
Avg per Recipient $233.03 $2.1K
Payment Type Count 5 5
Top Payment Type Consulting Fee Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.